Amneal Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
AMRX$21.38+0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net income | $159,920 | $78,360 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 144,250 | 174,345 |
| Unrealized foreign currency loss (gain) | 13,571 | (8,606) |
| Amortization of debt issuance costs and discount | 12,141 | 18,716 |
| Reclassification of cash flow hedge | 8,730 | (1,713) |
| Loss on refinancing | 9,270 | 31,365 |
| Intangible asset impairment charges | 975 | 22,784 |
| Research and development equipment impairment charges | 13,832 | — |
| Non-cash property losses | 5,035 | — |
| Change in fair value of contingent consideration | (6,000) | — |
| Stock-based compensation | 29,723 | 23,751 |
| Inventory provision | 64,981 | 59,326 |
| Other operating charges and credits, net | 4,689 | 3,575 |
| Changes in assets and liabilities: | ||
| Trade accounts receivable, net | (122,423) | (110,228) |
| Inventories | (158,346) | (66,846) |
| Prepaid expenses, other current assets and other assets | (113,073) | (20,173) |
| Related party receivables | 203 | (830) |
| Accounts payable, accrued expenses and other liabilities | 17,590 | 2,744 |
| Related party payables | (34,756) | 3,107 |
| Net cash provided by operating activities | 50,312 | 209,677 |
| Cash flows from investing activities: | ||
| Acquisition of Kashiv, net of cash and restricted cash acquired | (421,047) | — |
| Purchases of property, plant and equipment | (70,659) | (48,290) |
| Acquisition of intangible assets | (96,603) | (12,514) |
| Deposits for future acquisition of property, plant and equipment | (28,376) | (7,384) |
| Proceeds from sale of property, plant and equipment | — | 1,379 |
| Net cash used in investing activities | (616,685) | (66,809) |
| Cash flows from financing activities: | ||
| Payments of principal on debt, revolving credit facilities and financing leases | (293,172) | (2,805,384) |
| Proceeds from issuance of debt | 529,853 | 2,694,750 |
| Payments of deferred financing and refinancing costs | (7,549) | (74,973) |
| Borrowings on revolving credit facilities | 280,000 | 218,000 |
| Proceeds from exercise of stock options | 516 | 1,407 |
| Employee payroll tax withholding on restricted stock unit and performance stock unit vesting | (44,696) | (21,957) |
| Tax and other distributions to non-controlling interests | (29,571) | (38,825) |
| Proceeds from alliance party | 510 | 5,572 |
| Acquisition of non-controlling interest | (400) | — |
| Net cash provided by (used in) financing activities | 435,491 | (21,410) |
| Effect of foreign exchange rate on cash | (1,804) | (1,471) |
| Net decrease in cash, cash equivalents, and restricted cash | (132,686) | 119,987 |
| Cash, cash equivalents, and restricted cash - beginning of period | 312,939 | 118,420 |
| Cash, cash equivalents, and restricted cash - end of period | $180,253 | $238,407 |
| Cash and cash equivalents - end of period | $157,399 | $201,249 |
| Restricted cash - end of period | 14,174 | 34,727 |
| Long-term restricted cash included in other assets - end of period | 8,680 | 2,431 |
| Cash, cash equivalents, and restricted cash - end of period | $180,253 | $238,407 |
Consolidated Statements of Cash Flows (continued)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $151,671 | $156,447 |
| Cash paid, net for income taxes | $4,558 | $17,576 |
| Supplemental disclosure of non-cash investing and financing activity: | ||
| Contingent consideration for acquisition - related party | $389,000 | $— |
| Class A common stock issued in connection with the Kashiv Acquisition | $491,610 | $— |
| Acquisition of product rights and licenses | $602 | $411 |
| Loan for land purchase - related party | $— | $482 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.